ImmunityBio, Inc.
IBRX
$2.13
$0.010.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 433.76% | 2,568.79% | 41,172.50% | 5,084.17% | 7,160.98% |
| Total Other Revenue | 84.87% | -92.98% | -80.00% | 148.92% | 85.37% |
| Total Revenue | 425.07% | 2,423.88% | 41,192.50% | 5,333.09% | 7,346.34% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 422.17% | 2,410.89% | 41,047.50% | 5,333.09% | 7,346.34% |
| SG&A Expenses | 0.99% | -13.56% | -21.53% | 25.13% | 11.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.54% | -2.66% | -15.00% | -9.08% | 7.66% |
| Operating Income | 30.68% | 28.24% | 32.32% | 17.87% | -0.15% |
| Income Before Tax | 21.51% | 31.41% | 3.15% | 74.65% | 10.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.55% | 31.21% | 3.33% | 74.65% | 10.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8.70% | -5.00% | -4.76% | -22.73% | -61.67% |
| Net Income | 21.55% | 31.22% | 3.33% | 74.65% | 10.31% |
| EBIT | 30.68% | 28.24% | 32.32% | 17.87% | -0.15% |
| EBITDA | 31.82% | 28.99% | 33.14% | 18.36% | -0.33% |
| EPS Basic | 42.37% | 46.81% | 23.73% | 76.85% | 35.77% |
| Normalized Basic EPS | 42.34% | 46.98% | 23.68% | 76.86% | 35.73% |
| EPS Diluted | 50.56% | 47.90% | 24.00% | 73.37% | 25.13% |
| Normalized Diluted EPS | 42.19% | 46.98% | 23.68% | 76.90% | 35.89% |
| Average Basic Shares Outstanding | 36.03% | 29.30% | 26.80% | 9.51% | 39.63% |
| Average Diluted Shares Outstanding | 35.62% | 29.30% | 26.80% | 9.70% | 40.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |